Escutia-Cuevas HH, Merino-Rajme JA, Alcántara-Meléndez MA, Espinoza-Rueda MA, Fernández-Ceseña E, García-García JF, Morales-Portano JD, Muratalla-González R, Ordoñez-Salazar BA

Language: English
References: 20
Page: 102-111
PDF size: 591.08 Kb.

ABSTRACT

Background: Aortic stenosis is the most common valvular heart disease worldwide. The prognosis is adverse without a valve replacement. Transcatheter aortic valve implantation (TAVI) has proven to be an effective treatment in high-surgical risk patients. Recent trials have highlighted the non-inferiority of TAVI compared with open surgery in patients with intermediate surgical risk. Case report: A 76-year-old man with severe aortic stenosis and intermediate surgical risk (STS-PROM 4.8%) who underwent TAVI with no complications. Results: Hospital discharge was decided five days after the procedure and continued outpatient follow-up. After two years remains in NYHA functional class I with a normofunctional percutaneous prosthesis. Conclusion: As this clinical case shows, TAVI has proven to be an effective treatment in patients with aortic stenosis and intermediate surgical risk. This is the first experience in this type of patients reported in our country.

REFERENCES

1. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005; 26 (24): 2714-2720.

2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003; 24 (13): 1231-1243.

3. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002; 106 (24): 3006-3008.

4. Jansen F, Werner N. Interventional treatment of the aortic valve : Current evidence. Herz. 2017; 42 (6): 548-553.

5. Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Feindel CM et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol. 2010; 55 (11): 1080-1090.

6. Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011; 123 (3): 299-308.

7. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, Treede H et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2010; 122 (1): 62-69.

8. Piazza N, Grube E, Gerckens U, den Heijer P, Linke A, Luha O et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention. 2008; 4 (2): 242-249.

9. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010; 363 (17): 1597-1607.

10. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011; 364 (23): 2187-2198.

11. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016; 374 (17): 1609-1620.

12. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017; 376 (14): 1321-1331.

13. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016; 387 (10034): 2218-2225.

14. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38 (36): 2739-2791.

15. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 70 (2): 252-289.

16. Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R et al. Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol. 2017; 70 (1): 42-55.

17. Ali N, Patel PA, Lindsay SJ. Recent developments and controversies in transcatheter aortic valve implantation. Eur J Heart Fail. 2018; 20 (4): 642-650.

18. Barbanti M, Capranzano P, Ohno Y, Attizzani GF, Gulino S, Immè S, Cannata S et al. Early discharge after transfemoral transcatheter aortic valve implantation. Heart. 2015; 101 (18): 1485-1490.

19. Urena M, Hayek S, Cheema AN, Serra V, Amat-Santos IJ, Nombela-Franco L et al. Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation. 2015; 131 (5): 469-477.

20. Barbanti M, Gulino S, Costa G, Tamburino C. Pathophysiology, incidence and predictors of conduction disturbances during Transcatheter Aortic Valve Implantation. Expert Rev Med Devices. 2017; 14 (2): 135-147.